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Abstract
Background: Pseudomonas fluorescens lectin (PFL) belongs to a recently discovered anti-HIV lectin family and
induces anoikis-like cell death of MKN28 gastric cancer cells by causing α2 integrin internalization through
recognition of high mannose glycans; however, the detailed anti-cancer mechanism is not fully elucidated.
Methods: Cell adherence potency of MKN28 upon PFL treatment was assessed using a colorimetric assay. Cell surface
molecules to which PFL bound were identified by peptide mass finger printing with Matrix Assisted Laser Desorption/
Ionization-time of flight mass spectrometry and their cellular localization determined by immunofluorescence
microscopy. Gene and protein expression in PFL-treated MKN28 cells were evaluated by microarray analysis and
western blot, and the function of these genes was evaluated by siRNA knock-down. A proliferation assay measured the
sensitivity of PFL-treated cancer cells to anti-cancer drugs. The effect of PFL on subcutaneous MKN28 tumor growth
and hepatic tumor formation in BALB/c nude mice was evaluated.
Results: The strength of MKN28 cell adherence in vitro to the extracellular matrix was impaired by PFL treatment,
consistent with the observation that PFL induces rapid downregulation of surface integrins. PFL also was found to bind
to cell surface epidermal growth factor receptor (EGFR). Surface EGFR molecules were endocytosed following PFL
binding, and were degraded in a time-dependent fashion. This degradation process was largely the result of
autophagy, as revealed by the increased expression of autophagic proteins. PFL-induced EGFR degradation was partly
inhibited by RAB7 siRNA as well as LC3 siRNA, and internalized EGFR colocalized with ATG9 at 48 h post-PFL treatment,
suggesting that these proteins contribute to dynamic degradation induced by PFL. PFL-induced decrease in surface
EGFR rendered MKN28 cells susceptible to gefitinib, a selective inhibitor of EGFR tyrosine kinase. In vivo experiments
showed that PFL-treated MKN28-EGFP cells injected in the portal vein of BALB/c nude mice failed to form tumor
colonies on the liver, and intratumoral injection of PFL significantly inhibited tumor growth.
Conclusion: PFL-mediated downregulation of integrin and EGFR contributes to the inhibition of tumor growth in vitro
and in vivo. This novel anti-cancer mechanism of PFL suggests that this lectin would be useful as an anti-cancer drug
or an adjuvant for other drugs.
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Background
Lectins, carbohydrate-binding proteins, are distributed
ubiquitously in a variety of organisms. Among them,
high mannose-binding lectins have attracted attention
for biomedical research as promising biomolecules with
anti-viral or anti-tumor activities [1]. Recently, a novel
high mannose-binding lectin family has been discovered
in lower organisms such as bacteria, cyanobacteria and
marine algae [2]. This family includes well-characterized
cyanobacterial OAA from Oscillatoria agardhii [2, 3],
red algal ESA-2 from Eucheuma serra [4] and KAA-2
from Kappaphycus alvarezii [5], bacterial PFL from
Pseudomonas fluorescens Pf0-1 [6], and several other
homologous proteins [7]. These proteins commonly
show exclusive specificity for high mannose N-glycans
but no monosaccharide-binding [2, 4–6]. At low nano-
molar levels, some of these lectins exhibit potent anti-
viral activity against HIV and influenza viruses, through
recognition of high mannose glycans on virus envelope
glycoproteins [2–6]. At micromolar or higher concentra-
tions, some lectins, such as ESA-2 and PFL, show cytotox-
icity for various cancer cells [6, 8]. It has been proposed
that the cell death of colon carcinoma Colon26 cells
induced by ESA-2 is mediated by the apoptosis path-
way [8]. By contrast, our recent study demonstrated
that PFL induces anoikis-like cell death of MKN28
human gastric cancer cells via interaction with cell surface
integrin molecules [6]. This cell death that accompanies
loss of cell adhesion was presumably due to the rapid in-
ternalization of cell surface integrins upon direct binding
of PFL to high mannose glycans on α2 integrin; however,
the detailed mechanism of death signaling has not been
fully elucidated.
In this study, we have further explored the PFL target
molecule(s) on MKN28 cells and identified the involve-
ment of epidermal growth factor receptor (EGFR). Intri-
guingly, similar to the dynamic redistribution of integrins,
cell surface EGFR also internalized to the cytoplasm
following PFL treatment. We therefore investigated the
adjuvant effect of PFL in combination with EGFR inhibit-
ing anti-cancer drugs currently in clinical use. Moreover,
to address the anti-cancer mechanism induced by PFL
in more detail, the participation of the autophagy and
apoptosis pathways was analyzed. Finally, the in vivo




The antibodies against autophagy-related proteins (Beclin1,
ATG3, ATG 5, ATG 7, ATG 9A, ATG 12, ATG 13, LC3,
and HSPB8), apoptosis-related proteins (caspase-9, cleaved
caspase-9, caspase-7, cleaved caspase-7, caspase-3, and
cleaved caspase-3) and RAB7 were purchased from Cell
Signaling Technology (CST, Japan). The anti-actin antibody
was purchased from Santa Cruz. The Alexa-conjugated
anti-mouse and anti-rabbit IgG were purchased from Life
Technologies. Small interfering RNA (siRNA) for ATG9A,
HSPB8, LC3, RAB7 and non-targeting control siRNA were
purchased from Thermo Scientific (Lafayette, CO). siRNAs
for Beclin1 and ATG5 were purchased from CST. Gefitinib
was purchased from Cayman chemical (MI).
Cell lines and culture conditions
The gastric cancer cell line MKN28 was maintained in
RPMI-1640 medium (Wako, Japan) supplemented with
10 % fetal bovine serum (FBS, GIBCO), 100 IU/mL peni-
cillin G sodium, and 100 μg/mL streptomycin sulfate as
described previously [6]. Both MKN28-EGFR and the hu-
man colon cancer cell line HT-29 Luc cells were obtained
from Dr. Yanagihara at National Cancer Center Research
Institute, and were maintained as described above.
In vitro cell adhesion assay
The effect of PFL on cell adhesion was evaluated using
the CytoSelect cell adhesion assay (Cell Biolabs, San
Diego, USA). MKN28 cells were treated with 10 μM PFL
for 3 h in RPMI-1640 medium with 10 % FBS. The cell
suspensions were allowed to attach to an ECM-coated
48-well plate for 90 min at 37 °C. Adherent cells were
stained and extracted according to manufacturer’s proto-
cols. Extracted samples were measured at 560 nm in a
plate reader (1420 multilabel counter, PerkinElmer).
Isolation of PFL-binding molecule(s) from MKN28 cell
The cell surface molecule(s) that interacted with PFL were
identified as described previously [6]. Briefly, biotinylated-
PFL (200 μg) was added to confluent MKN28 cells and in-
cubated for 2 h at room temperature. The cells were lysed
in 800 μL of RIPA buffer (50 mM Tris–HCl, pH 7.6,
150 mM NaCl, 1 % Nonidet P40, 0.5 % sodium deoxycho-
late, protease inhibitor cocktail, 0.1 % SDS). Subsequently,
100 μL of biotin-capture avidin beads (Adar Biotech, Israel)
was added to the cell lysate and incubated overnight at
4 °C with gentle agitation. Captured proteins on beads
were eluted with 50 μL of SDS-PAGE sample buffer
(62.5 mM Tris, pH 6.8, 2 % SDS, 10 % glycerol, 1 % mer-
captoethanol, and 0.003 % bromphenol blue) for 15 min at
90 °C and subjected to SDS-PAGE. The protein band spe-
cific for the PFL treatment fraction was analyzed by Matrix
Assisted Laser Desorption/Ionization-time of flight mass
spectrometry (MALDI-TOF MS) after in-gel digestion
with trypsin. The peptide mass finger printing data was
searched using Mascot software (Matrix Science, Japan).
Cellular localization of α2 integrin and EGFR
The cellular distribution of EGFR upon PFL treatment
was observed by immunofluorescence microscopy as
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described previously [6]. Confluent MKN28 cells grow-
ing on coverslips in a 6-well plate were treated with
30 μg/mL Alexa488-conjugated-PFL in RPMI-1640 and
incubated for various periods of time. The cells were
fixed with 80 % acetone and incubated with mouse
monoclonal anti-EGFR antibody (Thermo Scientific,
UK) at 37 °C for 1 h. Subsequently, the cells were incu-
bated with Alexa568-conjugated goat anti-mouse IgG
antibody (Life technologies, Japan) at 37 °C for 1 h. The
cells were mounted using Vectashield with DAPI (Vec-
tor Laboratories) and were observed using a confocal
laser scanning microscope (IX70; Olympus, Japan). The
cellular distribution of EGFR together with ATG9 was
examined in a similar way using mouse anti-EGFR anti-
body and rabbit anti-ATG9 antibody. Accordingly, a dis-
tinct secondary antibody was employed to visualize
EGFR and ATG9, using Alexa488-conjugated goat anti-
mouse IgG antibody and Alexa568-conjugated goat anti-
rabbit IgG antibody, respectively. The cellular distribu-
tion of α2 integrin following PFL treatment was ob-
served as above after incubation with 10 μM PFL for
24 h.
Western blotting
Expression of cellular proteins related to the autophagy
and apoptosis pathways were determined by western
blotting. Confluent MKN28 cells cultured in 6-well
plates were incubated with 2 μM PFL in RPMI-1640
with FBS for 3, 24, 48 and 72 h, and the cells were lysed
with 800 μL of RIPA buffer for 30 min on ice with gentle
shaking until the cells were completely lysed. Portions of
each sample were applied to SDS-PAGE and visualized
by western blotting. The proteins were detected using a
specific rabbit antibody (1:1000) against each protein. A
horseradish peroxidase (HRP)-conjugated anti-rabbit
IgG (1:10,000) was used to visualize the signal by ECL
prime (GE healthcare, UK).
Adjuvant effect of PFL for anti-cancer drugs
The susceptibility of MKN28 cells to gefitinib was evalu-
ated by measuring cell proliferation using the CellTiter
96 cell proliferation assay (Promega, Madison, WI). Cells
seeded on 96-well microplates were pretreated with
2 μM PFL for 24 h. The cells were washed once with
RPMI-1640 and incubated for 72 h with various concen-
trations of gefitinib in RPMI-1640 medium with 10 %
FBS. The cells were subsequently incubated with 20 μL
of MTS reagent for 1 h at 37 °C and measured with a
microplate reader (1420 multilabel counter, PerkinEl-
mer) at 490 nm. The sensitivity of another colon cancer
line, HT-29 Luc, to 5-Fluorouracil (5-FU) also was tested
to evaluate the effect of co-incubation of anti-cancer
drugs with PFL. These cells were incubated with various
concentrations of 5-FU for 96 h in the presence or
absence of 0.5 μM PFL, and the cell survival ratio was
determined by CellTiter-Glo luminescent cell viability
assay (Promega, Madison, WI).
DNA microarray analysis
MKN28 cells were incubated with 2 μM PFL in RPMI-
1640 containing 10 % FBS for 24, 48, and 72 h, and PFL-
untreated cells were incubated for 24 h without PFL (as
a control for comparing gene expression level). Total
RNA from the cells was extracted with the RNeasy kit
(QIAGEN, Valecia, CA) and 100 ng of each RNA was
subjected to Aligent Expression Array Analysis with Sur-
ePrint G3 Human GE 8x60K v2 (Takara Bio, Japan). The
expression levels of genes at each time were determined
and compared with those of the control RNA from PFL-
untreated cells.
Effect of siRNAs on PFL-induced EGFR degradation
MKN28 cells cultured in 24-well plates were transfected
with 100 nM siRNA in non-serum RPMI-1640 using
DharmaFECT transfection reagents (Thermo Scientific,
Lafayette, CO). At 24 h post-transfection, the culture
medium containing the siRNA was removed and the
cells were washed once with RPMI-1640. Then, the cells
were incubated with 2 μM PFL in RPMI-1640 with FBS
for 72 h, and cell extracts for western blotting were pre-
pared as described above. Expression of EGFR was
assessed by incubating with rabbit anti-EGFR antibody
(CST, Japan) followed by HRP-conjugated anti-rabbit
IgG (CST, Japan).
Mice
Animal experiments were approved by the animal ethics
committee of the Yasuda Women’s University (approval
number: 1120) and carried out under guidelines to
minimize suffering. Experimental mice were housed in
an approved clean facility, in a room with a controlled
light/day cycle and temperature.
In vivo tumor formation assay
Seven-week-old female BALB/c nude mice (Clea Japan)
were bred under SPF conditions. MKN28-EGFP cells
(1 × 107 cells/mL) in 100 μL RPMI-1640 were injected
into the portal vein to implant the tumor cells. In PFL-
treated groups, the cells were pre-incubated with 10 μM
PFL for 3 h in RPMI-1640 with 10 % FBS followed by
washing with the same medium without the lectin. The
tumor colonies, formed in the liver 4 weeks after tumor
implantation, were observed directly or using an in vivo
imaging system (IVIS; Xenogen, LUMINA II, CA) after
dissection. In vivo tumor formation experiments were
performed according to the guidelines for animal experi-
ments established by Yasuda Women’s University.
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In vivo effect of PFL on tumor growth in nude mice
The experiment was performed according to the guide-
lines for animal experiments established by Yasuda
Women’s University. Six-week-old female BALB/c nude
mice (Clea Japan) were bred under SPF conditions.
MKN28-EGFP cells (1 × 107 cells) in 100 μL RPMI-1640
were subcutaneously injected at both ventral regions of
the mice to implant the tumor cells. Intratumoral injection
of PFL (1 mg/mL) in 100 μL phosphate buffered saline
(PBS) was performed 1, 3, and 7 days after tumor cell im-
plantation. The same volume of PBS was used as a vehicle
control. The length and width of the implanted tumor
mass were measured every third day following the initial
injection, and the tumor volume was estimated.
Results
PFL changes cell adherence strength by inducing
intracellular trafficking of integrin
Our previous study demonstrated that the bacterial lec-
tin PFL induces intracellular trafficking of α2 integrin in
MKN28 gastric cancer cells through the specific recogni-
tion of high mannose glycans on α2 integrin [6]. We
therefore tested the extracellular matrix (ECM)-binding
profiles of MKN28 cells after PFL treatment using a col-
orimetric assay and ECM-coated plates. In the absence
of PFL, MKN28 cells attached strongly to collagen type I
and IV, and to fibronectin (Fig. 1a). However, after
10 μM PFL treatment for 3 h, the adhesive properties of
MKN28 cells to these ECMs were completely abolished,
as shown in Fig. 1a. The α2 integrin molecules on the
cell surface were significantly down-regulated by treat-
ment with 10 μM PFL for 24 h (Fig. 1b). The loss of cell
adherence strength caused by PFL is well correlated with
the rapid down regulation of cell surface integrins, which
has been previously described [6].
Identification of cell surface molecules targeted by PFL
In our previous study, we demonstrated that biotinylated
PFL interacts directly with high mannose glycans on α2
integrin expressed on the surface of MKN28 cells [6]. To
further explore the cell surface molecule(s) to which PFL
bound, biotin-PFL was incubated with MKN28 cells and
the molecules bound to biotin-PFL were co-precipitated
with avidin-coated beads. The proteins trapped on the
beads were analyzed by SDS-PAGE and the specific band
in the PFL fraction (Fig. 2a, left panel, arrow 1 or 2) was
identified by peptide mass fingerprinting using MALDI-
TOF mass spectrometry after in gel digestion with trypsin.
We searched a database for the peptide mass data ob-
tained from the band identified by arrow 1 (Fig. 2a, right
panel). The band, with a weight of 170 kDa (arrow 1) was
identified as EGFR, with a probability score of 92
(p < 0.05). The 150 kDa band (arrow 2) was α2 integrin, as
was previously identified [6].
PFL induces intracellular trafficking of EGFR
Cellular localization of EGFR upon PFL treatment was
then examined using confocal fluorescence microscopy.
Fluorescent-labeled PFL (Alexa488-PFL) was used to track
PFL localization. EGFR was detected with an anti-EGFR
monoclonal antibody followed by Alexa568-conjugated
secondary antibody. As shown in Fig. 2b (left panel), PFL
induced rapid trafficking of surface EGFR to the cyto-
plasm. Treatment with PFL for 10 min induced internal-
ization of EGFR, and the EGFR seemed to colocalize with
PFL. PFL-induced EGFR trafficking was inhibited effect-
ively by yeast mannan, a glycoprotein bearing high man-
nose glycans, suggesting the interaction between PFL and
EGFR was mediated by these glycans (Fig. 2b, right panel).
Western blot revealed that the bands corresponding to
EGFR were diminished in a time-dependent fashion in the
presence of PFL (Fig. 2c), suggesting the contribution of
some degradation process, such as autophagy after PFL-
induced EGFR internalization. The protein level of EGFR
was only reduced in the presence of PFL, as shown in
Fig. 2c (right panel).
PFL induces autophagy but not apoptosis in MKN28 cells
To determine whether PFL stimulates autophagy in
MKN28 cells, expression levels of autophagy-related
Fig. 1 a Change of adhesive properties of cells to ECM after PFL
treatment. MKN28 cells were treated with 10 μM PFL for 3 h and
spread on ECM-coated plates. The cells were allowed to attach to
ECM-coated plates for 90 min at 37 °C. Attached cells were detected
by a colorimetric method. Controls were evaluated in the same way
without PFL. b Down regulation of surface α2 integrin in MKN28
cells after a 24 h incubation with 10 μM PFL. Cellular distribution of
α2 integrin after PFL treatment was observed by immunofluorescence
microscopy using anti- α2 integrin antibody
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proteins were estimated by western blotting. MKN28
cells were incubated with 2 μM PFL in RPMI-1640
medium with 10 % FBS for 3–72 h. As shown in Fig. 3a,
time dependent increase of Beclin-1, Autophagy Related
3(ATG3), ATG5, ATG7, ATG9A, ATG12, and ATG13
was observed. The expression of ATG13, its phosphoryl-
ation state contributes to autophagy induction, has been
increased at early stage, 24 h after PFL treatment. Simi-
larly, Beclin-1 and ATG5, which are important for
vesicle nucleation and vesicle elongation, respectively,
showed increased expression 24 h after PFL treatment.
The autophagic marker LC3II, which is converted from
LC3I by the sequential action of ATG7 and ATG3, also ap-
peared at a relatively late stage, 48 h after PFL treatment.
The expression of HSPB8, a member of the small heat
shock protein (HSP) family that stimulates protein degrad-
ation by macroautophagy, was also increased by PFL treat-
ment. Consistent with increased expression of autophagy-
related proteins, the expression of autophagic genes also
was enhanced by PFL, as confirmed by microarray analysis
(Table 1, original data is available in Additional file 1: Table
e1). These data suggested that the internalized PFL-EGFR
complex triggered macroautophagy or chaperone-mediated




Fig. 2 a Identification of a cell surface molecule that interacts with PFL on MKN28 cells. The cells were treated with biotin-PFL and proteins that
bound to biotin-PFL were precipitated with avidin-coated beads. Proteins captured on beads were separated by SDS-PAGE (left panel) and the
protein specific for the PFL fraction (arrow 1) was analyzed by MALDI-TOF MS after in-gel digestion with trypsin. The peptide mass finger printing
data (right panel) thus obtained was searched using Mascot software. b Effect of PFL on cellular distribution of EGFR. The change of cellular
localization of EGFR induced by PFL was observed using confocal fluorescence microscopy. The distribution of Alexa-488 PFL (green) and EGFR
(red) are shown. Colocalization of Alexa-488 PFL and EGFR is shown as a yellow signal (Merge). Nuclei within the cells were stained with DAPI. In
the right panel, the effect of yeast mannan (YM) on PFL-induced trafficking of EGFR is shown. The change in distribution of EGFR (green) was
observed by confocal fluorescence microscopy. c Western blots show the protein levels of EGFR in MKN28 cells upon treatment with 2 μM PFL for 3,
24, 48, and 72 h and without treatment (shown as -). In the right panel, western blots show the protein levels of EGFR in MKN28 cells determined in
the presence or absence of 2 μM PFL
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A B
Fig. 3 Change of expression levels of autophagy or apoptosis related proteins in MKN28 cells after PFL treatment. After treatment with 2 μM PFL
for the indicated time, the cells were lysed and subjected to immunoblot analysis. Western blots show the protein expression detected for
autophagy-related proteins (a) and apoptosis-related proteins (b)
Table 1 Change of expression of autophagy related genes in MKN28 cells after PFL treatment
Total RNA from PFL-treated and untreated MKN28 cells was extracted and subjected to Aligent Expression Array Analysis with SurePrint G3 Human GE 8x60K v2
(Takara Bio, Japan). The expression level of each gene at each time was determined and compared with that of control RNA from PFL-untreated cells. Highlighting
indicates more than a 2-fold change in the expression level.
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compartment. Conversely, PFL did not activate the apop-
tosis pathway, as shown in Fig. 3b, since no cleaved forms
of caspase-9, caspase-7 nor caspase-3 were detected.
A substantial amount of internalized EGFR was observed
as assembled small particles 48 h after PFL treatment, as
shown in Fig. 4a. ATG9A, an integral membrane protein
required for autophagosome formation, was induced by
PFL treatment and colocalized with EGFR. The protein ex-
pression level of ATG9A at 48 h was increased, as judged
from the intensity of red fluorescence compared to that of
the PFL-untreated control cells, consistent with the results
of western blotting (Figs. 3a and 4b).
RAB7 is essential for PFL-induced EGFR degradation
RNA expression of the RAB family proteins, considered
molecular switches of membrane traffic, were found to
be up- or down-regulated in PFL-treated MKN28 cells
by microarray analysis (Table 2). Among them, expression
of RAB7, which is known as a common modulator in
endocytosis and autophagy, was increased by the presence
of PFL (Table 2). Consistent with this observation, the
protein level of RAB7 was elevated significantly in PFL-
treated MKN28 cells (Fig. 5a). PFL treatment triggered de
novo synthesis of a key factor of membrane traffic and au-
tophagy. We therefore tested the effect of RAB7 siRNA on
PFL-induced EGFR degradation. As shown in Fig. 5b,
PFL-induced degradation of EGFR was partially rescued
by RAB7 siRNAs, as well as by LC3 siRNA, but not
ATG9A and HSPB8 siRNAs or control siRNA, indicating
that RAB7 and LC3 were essential for EGFR degradation.
PFL changes the sensitivity of cancer cells to anti-cancer drugs
The remarkable EGFR downregulation caused by PFL was
expected to enhance the effect of EGFR-targeting drugs.
To test the adjuvant effect of PFL for gefitinib, a selective
inhibitor of EGFR tyrosine kinase, MKN28 cells were pre-
treated with 2 μM PFL for 24 h prior to gefitinib adminis-
tration. After removing the medium containing PFL, the
cells were incubated with various concentrations of gefi-
tinib for 72 h. As shown in Fig. 6a (left panel), the cancer
cells pretreated with PFL showed increased sensitivity to
gefitinib at 10 and 20 μM. Co-incubation of 0.5 μM PFL
A
B
Fig. 4 Involvement of ATG9 in PFL-induced intracellular trafficking of EGFR. a MKN28 cells were incubated with 10 μM PFL for 48 h. EGFR and
ATG9 were visualized by confocal fluorescence microscopy. Representative photomicrographs show the cellular localization of EGFR (green) and
ATG9 (red); colocalization of both proteins is represented as a yellow signal (merged panel). b Histograms represent the expression of ATG9 in
MKN28 cells after 2 μM PFL treatment. Protein expression was determined by immunoblot analysis
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with gefitinib also enhanced sensitivity, although PFL at
this concentration was not cytotoxic by itself (Fig. 6a, right
panel). To further explore the adjuvant effect of PFL, we
tested the 5-FU sensitivity of another cancer cell line, HT-
29 Luc cells, in the presence or absence of PFL. As shown
in Fig. 6b, 0.5 μM PFL was not harmful to HT-29 Luc by
itself, however, 5-FU sensitivity of the cells was increased
in the presence of PFL.
PFL exhibits an in vivo anti-tumor effect in a mouse model
To test the in vivo effect of PFL, we employed a mouse
model of liver metastasis using portal vein injection of
MKN28-EGFP cells. Prior to tumor cell implantation, the
cells for PFL treated groups were incubated with 10 μM
PFL for 3 h, the same condition used in the in vitro adhe-
sion assay described above, then washed with medium to
remove unbound lectin. Aliquots of the cells (1 × 106 cells)
Table 2 Change of expression levels of RAB related genes in MKN28 cells after PFL treatment
Total RNA from PFL-treated and untreated MKN28 cells was extracted and subjected to Aligent Expression Array Analysis with SurePrint G3 Human GE 8x60K v2
(Takara Bio, Japan). The expression level of each gene at each time was determined and compared with that of control RNA from PFL-untreated cells. Highlighting
indicates more than a 2-fold change in the expression level.
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were injected into the portal vein of BALB/c nude mice
and, 4 weeks after implantation, tumor colonies formed in
the dissected liver were observed by fluorescence derived
from constitutively expressed EGFP in MKN28 cells with
IVIS. As shown in Fig. 7a, tumor formation at the liver
was inhibited significantly in PFL-treated groups. This
effect might be partly attributable to the impaired cell ad-
herence strength of MKN28-EGFP cells to the liver tissue,
where collagen IV is abundant. Other factors, such as a
dysfunction of cell proliferation, could be involved in PFL-
induced tumor suppression in the liver.
Finally, the in vivo effect of PFL on the growth of sub-
cutaneous MKN28 tumors in BALB/c nude mice was
evaluated. PFL (100 μg) in PBS was injected three times
intratumorally 1, 3 and 7 days after tumor implantation.
As shown in Fig. 7b, tumor volumes or fluorescence de-
rived from EGFP expressed in MKN28 cells in PFL-
treated groups was dramatically decreased, indicating
that the growth of tumors, compared with the control,
was inhibited by PFL treatment. In addition, no severe
symptoms or toxicity, such as decrease in body weight,
was observed following PFL treatment.
Discussion
In the present study, we demonstrated that the high
mannose binding bacterial lectin PFL induced rapid
intracellular trafficking of both EGFR and α2 integrin in
MKN28 gastric cancer cells. The adherence strength of
MKN28 cells to ECM was dramatically abolished by PFL
treatment, correlating with the loss of cell surface
A
B
Fig. 5 Involvement of RAB7 in PFL-induced EGFR degradation. a Western blots show the protein expression of RAB7 in MKN28 cells treated with
PFL. The cells were incubated with 2 μM PFL in RPMI-1640 with FBS for the indicated time and protein expression was analyzed and quantified
by immunoblotting. b Inhibition of EGFR degradation induced by PFL with RAB7 siRNA. MKN28 cells were incubated with various siRNAs against
ATG9A, LC3, HSPB8, and RAB7 in RPMI-1640 without FBS for 24 h and subsequently incubated with 2 μM PFL in RPMI-1640 with FBS. As a
reference, non-targeting control siRNA was used. Western blots show the EGFR expression for each sample (left panel) and the knock-down
efficiency of each siRNA (right panel). The histogram (bottom panel) displays the quantified expression of EGFR from each condition; asterisks indicate
values that were significantly different (p < 0.05) from control as revealed by one way ANOVA
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integrins. Activated EGFR transiently modulates α2 in-
tegrin cell surface expression and stimulates integrin
trafficking via caveolae/raft-mediated endocytosis [9].
Furthermore, physical and functional association be-
tween integrins and EGFR also has been demonstrated
[10, 11]. Such cross-talk between integrins and EGFR
has been hypothesized to play a critical role in cancer
progression [12]. It is still unclear whether PFL bound to
glycans of integrin and EGFR independently, or to those
of integrin/EGFR complexes. In either case, we assume
that both molecules internalized by PFL would be even-
tually degraded, resulting in dysfunction of cell attach-
ment and proliferation. Since high mannose EGFR has
reported to represent a novel tumor-specific antigen
[13], PFL would be useful as a cancer targeting material.
Recently, β1 integrin-silenced cells were reported to ex-
hibit defective activation of EGFR signaling, leading to
increased sensitivity to gefitinib [14]. Similarly, we ob-
served that PFL enhanced the susceptibility of MKN28
cells to gefitinib, possibly due to EGFR downregulation.
Moreover, enhanced drug sensitivity of other cancer cell
lines in the presence of PFL also was observed. For in-
stance, the 5-FU sensitivity of HT29 colon cancer cells
was increased in the presence of 0.5 μM PFL, a concentra-
tion that was not harmful to the cells, although the effect
of PFL was limited compared with EGFR drugs. The mech-
anism behind this observation is yet to be clarified; how-
ever, it is plausible that PFL might activate endocytosis
transiently during integrin/EGFR internalization, thereby
facilitating uptake of extracellular substances.
Our data suggest that the internalized integrin/
EGFR associated with PFL was degraded by autoph-
agy, a mechanism that eliminates damaged proteins,
aged proteins and organelles, or harmful aggregated
proteins [15–17]. Expression of many autophagic proteins
in MKN28 cells was elevated significantly by PFL treat-
ment, but expression of activated apoptotic proteins was
hardly detectable. Although we could not rule out the
possibility that both autophagy and apoptosis might occur
in PFL-treated cancer cells, because both phenomena are
reported to cross-talk through shared molecules such as
ATG5 by taking either the calpain-cleaved or non-cleaved
form [18, 19], the present data indicate that PFL primarily
induces autophagy.
Some plant lectins are reported to induce autophagy
in cancer cells via a mitochondria-mediated pathway
A
B
Fig. 6 Enhanced sensitivity of cancer cells to anti-cancer drugs following PFL treatment. a Enhanced sensitivity of MKN28 cells to gefitinib following
PFL treatment. Graphs display the viability of MKN28 cells treated with 2 μM PFL for 24 h, then incubated with various concentration of gefitinib for
72 h. Cell viability was determined by a conventional MTS assay. A representative experiment is shown. Effect of co-incubation of gefitinib with 0.5 μM
PFL was evaluated (right panel) in the same manner. b Enhanced sensitivity of HT-29 Luc cells to 5-FU by PFL treatment. The cells were incubated with
various concentration of 5-FU for 96 h in the presence or absence of 0.5 μM PFL. Histograms represent the cell viability as determined by CellTiter-Glo
luminescent cell viability assay. Asterisks indicate values significantly different (p < 0.01) between PFL-treated and non-treated cells
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[20]. For example, legume lectin Concanavalin A (ConA),
which recognizes high mannose N-glycans as well as
monosaccharides including mannose, binds to cell mem-
brane glycoproteins and is internalized and accumulates in
mitochondria, resulting in mitochondrial dysfunction and
induction of autophagy to degrade these mitochondria
[21]. Polygonatum cyrtonema lectin, which belongs to the
GNA-related lectin family, induces cancer cell autophagy
by promoting the ROS-p38-p53 pathway [22]. By contrast,
PFL-induced autophagy is mediated by integrin/EGFR in-
ternalization, a mechanism that has not been reported so
far, although other surface glycoproteins with high man-
nose glycans might be involved in this process as well.
Following PFL-induced receptor endocytosis, the asso-
ciation of EGFR with vesicular trafficking proteins such
as RAB7 was observed. RAB7, a member of small RAB
GTPase family, is known as a common modulator in
endocytosis and autophagy. It is involved not only in the
maturation of endosomes and autophagosomes, but also
in the trafficking of cargos along microtubules and in fusion
with lysosomes [15, 23–25]. Furthermore, it is reported that
functional RAB7 is required for the degradation of EGFR
by the lysosome [26]. In the present study, we observed in-
creased expression of RAB7, and that siRNA against RAB7
inhibited PFL-induced EGFR degradation, which suggest
that RAB7 plays an important role in this degradation
process. In addition, ATG9, a multipass transmembrane
protein necessary for optimal autophagy [27], increased in
expression in response to PFL treatment of MKN28 cells,
and colocalized with the internalized EGFR. Mammalian
ATG9 has been suggested to interact transiently with iso-
lation membranes and autophagosomes, but its actual
function is still controversial [28]. Although the detailed
mechanism of receptor membrane trafficking remains be
clarified, DNA microarray data suggest that multiple
molecules, including autophagic proteins, membrane
trafficking proteins, and motor proteins such as dynein,
might be involved in PFL-mediated receptor degradation.
A
B
Fig. 7 a In vivo tumor formation assay using PFL treated or non-treated MKN28-EGFP cells. MKN28-EGFP cells were incubated with 10 μM PFL for
3 h and injected to the portal vein of mice. Tumor colonies formed in the liver were detected 4 weeks post-injection. Photographs show the
dissected livers (upper panels). Tumor colonies are indicated by white arrows for control (left) and PFL-treated groups (right). Representative IVIS
images are shown at the bottom. b In vivo effect of PFL on tumor growth in nude mice. MKN28 cells were subcutaneously injected to mice and
tumors were allowed to grow. PFL (100 μg) in 100 μL PBS was intratumorally-injected three times 1, 3, and 7 days following tumor cells implantation.
The histogram displays tumor volume, represented as means ± SD (n = 10). Asterisks indicate values significantly different (p < 0.01) between
PFL-treated mice and the control. Representative IVIS images are shown for PFL-treated mice and the control
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The roles of autophagy are assumed to differ in different
stages of cancer development [29]. For example, autoph-
agy initially has a preventive role against cancer, but for
developed cancer cells, it can be utilized to promote can-
cer cell survival. Although we have no direct evidence as
to whether autophagy might contribute to PFL-induced
cell death and tumor suppression, it would be plausible
that PFL-induced autophagy ultimately affects cell sur-
vival, because it leads directly to defects in integrin and
EGFR signaling that are crucial for cell adhesion to appro-
priate location, migration and proliferation.
Direct administration of PFL to subcutaneous tumors
significantly reduced tumor growth in vivo. Other lectins,
such as ESA-2, which is from the same lectin family, re-
portedly exhibit potent anti-cancer activity when adminis-
tered intravenously or intraperitoneally in surface-bound
form in Span 80 vesicles to mice bearing subcutaneous tu-
mors [30]. Since this lectin family of proteins exhibit a
characteristic stable structure, i.e., a domain swap structure
with abundant β sheets [3, 7], it would be advantageous to
utilize them for clinical applications. Furthermore, it is
noteworthy that PFL enhanced the susceptibility of cancer
cells to anti-cancer drugs such as gefitinib. Serum levels of
surfactant protein D (SP-D), a C-type lectin with innate
immune functions, also reportedly are associated with gefi-
tinib efficacy [31]. Therefore, future work will be directed
toward evaluating the in vivo adjuvant effect of PFL with
various anti-cancer drugs to increase therapeutic efficacy
and reduce side effects.
Conclusion
Bacterial lectin PFL exhibited novel anti-cancer char-
acteristics as follows: 1) PFL had a cytotoxic effect on
cancer cells, inducing significant autophagy, which
was triggered by direct binding of PFL to cell surface
integrin/EGFR, causing internalization. PFL would
thus be useful as an autophagy stimulator to gain insights
into the molecular basis of autophagy in cancer cells. 2)
Down-regulation of cell surface integrin by PFL resulted
in impaired cell adhesion, and PFL treatment effectively
inhibited tumor formation in the liver, suggesting that PFL
might inhibit cancer metastasis. 3) Down-regulation of cell
surface EGFR by PFL rendered cancer cells susceptible to
gefitinib, suggesting that PFL potentially would be useful
as an adjuvant with other anti-cancer drugs.
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